A DRUG that shrinks tumours in patients with untreatable prostate cancer has shown “remarkable” results, scientists have said. The treatment, called VIR-5500, harnesses the body’s ...

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about managing side effects following prostate cancer treatment. While treatment ...

Men undergoing radiation therapy for prostate cancer who experience side effects early in treatment may face a higher risk of developing more serious long-term urinary and bowel health issues, ...

For many men with prostate cancer, weeks of daily treatments are no longer the norm. Jonathan Tward, MD, a radiation oncologist at Huntsman Cancer Institute, explains how image guidance, real-time ...

A drug for advanced prostate cancer has shown “remarkable” results in an early-stage trial, with patients who had previously stopped being receptive to treatment finding their tumours shrinking, ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...

The average age of men who get diagnosed is 67.

Doctors say active monitoring, hormone therapy and newer focal treatments are reshaping care decisions for men.

MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S.

Early trials of the drug VIR-5500 showed it shrinking tumours in some patients ...

Men undergoing radiation therapy for prostate cancer who experience side effects early in treatment may face a higher risk of developing more serious long-term urinary and bowel health issues, ...